OR WAIT null SECS
Jill Murphy is Editor of Pharmaceutical Technology.
June 29, 2023
This arrangement was approved by the shareholders at BELLUS on June 16, 2023, according to a company press release.
June 26, 2023
The companies hope address the need for efficient collection, cryopreservation, quality control, and logistics capabilities of leukapheresis materials to support various aspects of the cell therapy workflow.
This collaboration is the first commercialization into the United States and Canadian markets for Rio Biopharmaceuticals.
June 23, 2023
The guidance describes the CDER formal dispute resolution (FDR) procedures for eligible requestors or sponsors that wish to appeal a scientific and/or medical issue related to a final order.
June 20, 2023
The transaction is expected to close in the third quarter of 2023.
The new facility also provides a plan for scalable product production processes that can potentially be replicated by Vaxxas domestically and globally.